ClinicalTrials.Veeva

Menu

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3

Conditions

Neuralgia

Treatments

Drug: Pregabalin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00150436
1008-198

Details and patient eligibility

About

To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Must have met the inclusion criteria for preceding double-blind BID study in postherpetic neuralgia
  • Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.

Exclusion criteria

  • Patients cannot participate if they experienced a serious adverse event during preceding double-blind BID study which was determined to be related to the study medication.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems